Global Rare Disease Contract Research Organization Market Size, Share, and COVID-19 Impact Analysis, By Service Type (Drug Development Strategy, Clinical Trial Management, Data Management & Biostatistics, Regulatory & Consulting, and Other Specialist Services), By Therapeutic Area (Cardiovascular, Neuroscience, Ophthalmology, Oncology, and Metabolic & Other), By Phase (Pre-Clinical, Phase I, Phase II, Phase III, and Phase IV), By End-User (Pharma & Biotech Companies, Non-Profit & Gov’t Sponsors, Academic & Research Institutes, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Rare Disease Contract Research Organization (CRO) Market Size Insights Forecasts to 2035

• The Global Rare Disease Contract Research Organization (CRO) Market Size Was Estimated at USD 2.15 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 8.09% from 2025 to 2035
• The Worldwide Rare Disease Contract Research Organization (CRO) Market Size is Expected to Reach USD 5.06 Billion by 2035
• Asia Pacific is expected to grow the fastest during the forecast period.

According to a research report published by Spherical Insights and Consulting, The Global Rare Disease Contract Research Organization Market Size was worth around USD 2.15 Billion in 2024 and is Predicted to Grow to around USD 5.06 Billion by 2035 with a Compound Annual Growth Rate (CAGR) of 8.09% from 2025 and 2035. The industry for rare disease contract research organization (CRO) has several opportunities to grow due to an adding emphasis on case-centric, effective, and innovative results in the product trial design to post-marketing, by the top providers similar as IQVIA, Paraxel, Medpace, Labcorp, and technical establishment Ergomed.

Market Overview

The global industry of rare disease contract research organization encompasses specialized firms providing clinical trial operation, nonsupervisory strategy, and drug development services for rare and orphan disease conditions. A rare disease contract research organization is a specialized partner managing clinical trials for rare and orphan disease conditions, addressing unique challenges similar as small patient populations, limited natural history data, and complex logistics. There is specialized and complex regulatory needs for drug development, especially for technical small biotech enterprises, which drives the need for CROs for precision drug, innovative trial designs, and patient case-centric. Traditional randomized controlled trials, technological advancements like AI & digital health, and the emergence of cell & gene therapy are some of the key trends in the market.     

Innovation and market expansion are anticipated as a result of major players' growing R&D expenditures and expanding partnerships. In March 2026, PacBio and DNAstack collaborated on the Global HiFi Genome Network Hub. For investors, the partnership highlights PacBio’s push to extend the reach of its high-accuracy HiFi sequencing beyond individual labs into large-scale, international research networks.     

Report Coverage

This research report categorizes the rare disease contract research organization (CRO) market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the rare disease contract research organization (CRO) market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Global Rare Disease Contract Research Organization (CRO) Market.  

Driving Factors

The growing prevalence of rare diseases is primarily responsible for driving the market demand. For instance, an estimated 400 million people are affected by rare diseases worldwide, while in U.S., they affect 25-30 million people, which is approximately 1 in 10. The EU Orphan Regulation (Regulation (EC) No 141/2000) provides a specialized framework for developing medicines for rare diseases, positively affecting the demand for contract research organization. The surging pipelines in gene and cell therapies and favorable orphan drug regulations are significantly escalating the rare disease contract research organization (CRO) market. Additionally, managing complex, small-cohort trials for rare diseases needs specialized CROs offering adaptive designs, patient recruitment, and high-touch site support, with top providers like IQVIA, Paraxel, Medpace, are contributing to escalating the market for Global Rare Disease Contract Research Organization (CRO) Market.     

Restraining Factors

The Global Rare Disease Contract Research Organization (CRO) Market is restricted by factors like small & dispersed patient populations, increased development cost, strict regulatory hurdles, and lack of specialized site accessibility. Cross-border genomic-data privacy barriers also posses challenge to the market growth.

Market Segmentation

The Rare Disease Contract Research Organization (CRO) market share is classified into service type, therapeutic area, phase, and end-user.   

• The clinical trial management segment dominated the market with the largest share of about 54.5% in 2024 and is projected to grow at a substantial CAGR of about 9.15% during the forecast period.

Based on the service type, the Global Rare Disease Contract Research Organization (CRO) Market is divided into drug development strategy, clinical trial management, data management & biostatistics, regulatory & consulting, and other specialist services. Among these, the clinical trial management segment dominated the market with the largest share of about 54.5% in 2024 and is projected to grow at a substantial CAGR of about 9.15% during the forecast period. Clinical trial management is part of innovative technology, developed and maintained by CROs. Decentralized trial logistics and real-time oversight demand are driving the segmental market growth.

• The oncology segment accounted for the largest share of about 35.0% in 2024 and is anticipated to grow at the fastest CAGR of 9.10% during the forecast period.

Based on the therapeutic area, the Global Rare Disease Contract Research Organization (CRO) Market is divided into cardiovascular, neuroscience, ophthalmology, oncology, metabolic & other. Among these, the oncology segment accounted for the largest share of about 35.0% in 2024 and is anticipated to grow at the fastest CAGR of 9.10% during the forecast period. More than 500 orphan-designated drugs are commercially available worldwide for various rare diseases, out of which oncology has the most drugs. CAR-T and precision programs targeting low-cancer prevalence is contributing to drive the market growth in the oncology segment.  

• The phase III segment accounted for the major share of about 56.0% in the rare disease contract research organization (CRO) market and is anticipated to grow at about 8.9% CAGR during the forecast period.

Based on the phase, the Global Rare Disease Contract Research Organization (CRO) Market is divided into pre-clinical, phase I, phase II, phase III, and phase IV. Among these, the phase III accounted for the major share of about 56.0% in the rare disease contract research organization (CRO) market and is anticipated to grow at about 8.9% CAGR during the forecast period. Phase III trials are intended to evaluate a new drug’s safety, efficacy, and effectiveness, usually a challenging, expensive, and time-consuming procedure, especially when carried out in a population with a rare condition.

• The pharma & biotech companies segment accounted for the dominant market share of about 71.5% in 2024 and is anticipated to grow at about 8.7% CAGR during the forecast period.

Based on the end-user, the Global Rare Disease Contract Research Organization (CRO) Market is divided into pharma & biotech companies, non-profit & Gov’t sponsors, academic & research institutes, and others. Among these, the pharma & biotech companies segment accounted for the dominant market share of about 71.5% in 2024 and is anticipated to grow at about 8.7% CAGR during the forecast period. Companies with fewer than 50 employees outsource their major clinical operations to CROs, which contributes to driving the segmental market. For instance, in September 2025, SynaptixBio CEO Dan Williams discusses how small biotechnology companies are playing a pivotal role in advancing treatments for rare diseases, leveraging their agility and focus to drive innovation where larger pharmaceutical firms may hesitate.

Regional Segment Analysis of the Rare Disease Contract Research Organization (CRO) Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the rare disease contract research organization (CRO) market over the predicted timeframe.

North America is anticipated to hold the largest share of about 46.7% in the Global Rare Disease Contract Research Organization (CRO) Market over the predicted timeframe. The market ecosystem in North America is strong, due to CRO’s specialized services enabling pharmaceutical, biotech, and medical device companies to navigate complex study designs. The demand for rare disease contract research organization (CRO) has been driven by the region's increased volume of specialized therapeutic pipelines, significant regulatory incentives, and reliance on outsourcing complex small-cohort trials. For instance, in July 2025, Novotech is a recognized full-service CRO trusted by biotech and small to mid-sized pharmaceutical companies to advance their drug development programs at every phase. The United States is leading in the North America rare disease contract research organization (CRO) market, with about 84.9% regional share, owing to the robust biotechnology and pharmaceutical ecosystem and increasing clinical trials.

Asia Pacific is expected to grow at a rapid CAGR of about 9.4% in the Global Rare Disease Contract Research Organization (CRO) Market during the forecast period. The Asia Pacific area has a thriving market for rare disease contract research organization (CRO) due to its increasing need for efficient drug development, along with the region’s extensive patient population, for conducting clinical trials. Due to collaborative initiatives among healthcare professionals, researchers, patient organizations, and government entities, the market for rare disease contract research organization is being driven. For instance, in august 2025, Expecto Health Science, an emerging Asia-Pacific Contract Research Organisation (CRO) led by a highly experienced leadership team, announced a strategic collaboration with VertisPro, a leader in AI-driven patient acquisition solutions. China is the dominating country in the Asia Pacific rare disease contract research organization (CRO) market, with over 80.0% share, driven by massive patient population and huge R&D investment.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the rare disease contract research organization (CRO) market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Allucent
• Caidya          
• Charles River Labs          
• Ergomed          
• Fortrea    
• ICON plc          
• IQVIA     
• Labcorp Drug Development
• Linical
• Medpace
• Novotech
• Orphan-Reach
• Parexel
• Syneos Health
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Recent Development

• In February 2026, Polaryx Therapeutics, Inc. announced it has selected a contract research organization (CRO) to conduct SOTERIA, a phase 2 trial evaluating its lead candidate PLX-200 across four rare lysosomal storage disorders (LSDs).

• In January 2026, Mendra, Inc., a biopharmaceutical company built to advance promising therapies for rare disease medicines, utilizing artificial intelligence (AI), announced its launch in conjunction with the closing of an $82 million oversubscribed Series A financing.

• In October 2025, IDDI Strengthens Position as Contract Research Organization with Advanced Clinical Trial Design Solutions. The company’s advanced statistical methodologies and adaptive trial design capabilities are addressing critical challenges in drug development while improving efficiency, accuracy, and success rates of clinical trials.

• In April 2025, Comac Medical, a leading full-service Contract Research Organization (CRO) in Central and Eastern Europe, announced the appointment of a new CEO and Board Chair and the launch of an international expansion initiative. 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Global Rare Disease Contract Research Organization (CRO) Market based on the below-mentioned segments:  

Global Rare Disease Contract Research Organization (CRO) Market, By Service Type

• Drug Development Strategy
• Clinical Trial Management
• Data Management & Biostatistics
• Regulatory & Consulting
• Other Specialist Services

Global Rare Disease Contract Research Organization (CRO) Market, By Therapeutic Area

• Cardiovascular
• Neuroscience
• Ophthalmology
• Oncology
• Metabolic & Other

Global Rare Disease Contract Research Organization (CRO) Market, By Phase

• Pre-Clinical
• Phase I
• Phase II
• Phase III
• Phase IV

Global Rare Disease Contract Research Organization (CRO) Market, By End-User

• Pharma & Biotech Companies
• Non-Profit & Gov’t Sponsors
• Academic & Research Institutes
• Others

Global Rare Disease Contract Research Organization (CRO) Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa